Reflexion Pharmaceuticals

Reflexion Pharmaceuticals is a biopharmaceutical startup focused on developing a groundbreaking class of molecules aimed at addressing the limitations of biologics. With a mission to overcome the inherent challenges associated with protein-based drugs, particularly monoclonal antibodies, Reflexion Pharmaceuticals aims to tackle issues such as proteolytic instability, immunogenicity, and large size. By engineering therapies designed to mimic the affinity and specificity of antibodies while remaining "invisible" to the human body, the company aims to achieve superior proteolytic stability, reduced immunogenicity, and minimized off-target toxicity. Given their smaller size, these therapies have the potential for increased molar dosing and enhanced tissue penetration compared to conventional antibodies. Asserting that their platform can yield more effective and better-tolerated therapies than current biologics, Reflexion Pharmaceuticals operates within the biopharma and biotechnology sectors. Established in 1902, the company is currently headquartered in a location that is not specified. As of now, there is no public information available regarding the last investment and the investors involved. This innovative approach positions Reflexion Pharmaceuticals as an intriguing prospect for venture capital investment.